Ajmaline

Ajmaline

SCHEMBL30116336

CC[C@H]1[C@@H]2C[C@H]3[C@@H]4N(C)c5ccccc5C45C[C@@H](C2[C@H]5O)N3[C@@H]1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 3/20 1.00
KCNH2 Q12809 2/20 1.00
SCN5A Q14524 2/20 1.00
KMT2A Q03164 2/20 1.00
ADRA2B P18089 1/20 1.00
ADRA2C P18825 1/20 1.00
DRD3 P35462 1/20 1.00
OPRK1 P41145 1/20 1.00
MEN1 O00255 1/20 1.00
TSHR P16473 1/20 1.00
CACNA1F O60840 1/20 1.00
SCN1A P35498 1/20 1.00
SCN4A P35499 1/20 1.00
SCN7A Q01118 1/20 1.00
CACNA1D Q01668 1/20 1.00
CACNA1S Q13698 1/20 1.00
CACNA1C Q13936 1/20 1.00
SCN9A Q15858 1/20 1.00
SCN2A Q99250 1/20 1.00
SCN3A Q9NY46 1/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ajmaline SCHEMBL29620363 1.00 CYP2D6 (1.00) CYP2D6KCNH2SCN5AKMT2AADRA2B
Ajmaline SCHEMBL30892623 1.00 CYP2D6 (1.00) CYP2D6KCNH2SCN5AKMT2AADRA2B
Ajmaline SCHEMBL29811209 1.00 CYP2D6 (1.00) CYP2D6KCNH2SCN5AKMT2AADRA2B
Ajmaline SCHEMBL14029381 1.00 CYP2D6 (1.00) CYP2D6KCNH2SCN5AKMT2AADRA2B
Ajmaline SCHEMBL2787287 1.00 CYP2D6 (1.00) CYP2D6KCNH2SCN5AKMT2AADRA2B
Ajmaline SCHEMBL23295973 1.00 CYP2D6 (1.00) CYP2D6KCNH2SCN5AKMT2AADRA2B
Ajmaline SCHEMBL10422895 1.00 CYP2D6 (1.00) CYP2D6KCNH2SCN5AKMT2AADRA2B
Ajmaline SCHEMBL29354066 1.00 CYP2D6 (1.00) CYP2D6KCNH2SCN5AKMT2AADRA2B
Ajmaline SCHEMBL15384531 1.00 CYP2D6 (1.00) CYP2D6KCNH2SCN5AKMT2AADRA2B
Ajmaline SCHEMBL18950 1.00 CYP2D6 (1.00) CYP2D6KCNH2SCN5AKMT2AADRA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3370539-B1 ADSORPTION SYSTEM AND METHOD FOR OPERATING AN ADSORPTION SYSTEM FLAVOLOGIC GMBH (DE) 2025-07-02 EP disclosed
CN-118903120-A Combination of beta-lactam compound and probenecid and use thereof 伊泰伦治疗国际有限公司 2024-11-08 CN disclosed
US-12109197-B2 Combinations of β-lactam compounds and probenecid and uses thereof Iterum Therapeutics International Limited (IE) 2024-10-08 US disclosed
CN-117597327-A Pharmaceutical preparation 第一波动生物制药股份有限公司 2024-02-23 CN disclosed
US-20230218588-A1 COMBINATIONS OF BETA-LACTAM COMPOUNDS AND PROBENECID AND USES THEREOF Iterum Therapeutics International Limited (IE) 2023-07-13 US disclosed
EP-2938328-B1 MONOLITHIC PHARMACEUTICAL FORM FOR MODIFIED RELEASE OF AN ACTIVE INGREDIENT COMBINATION HENNIG ARZNEIMITTEL GMBH&CO KG (DE) 2023-07-05 EP disclosed
US-11554112-B2 Combinations of β-lactam compounds and probenecid and uses thereof Herum Therapeutics International Limited (IE) 2023-01-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11554112-B2 Combinations of β-lactam compounds and probenecid and uses thereof PEPD, BTD, NRDC CYP2D6 562/4885KCNH2 2687/4885SCN5A 1266/4885
US-12109197-B2 Combinations of β-lactam compounds and probenecid and uses thereof PEPD, BTD, NRDC CYP2D6 562/4885KCNH2 2687/4885SCN5A 1266/4885
US-20230218588-A1 COMBINATIONS OF BETA-LACTAM COMPOUNDS AND PROBENECID AND USES THEREOF PEPD, NRDC, BTD CYP2D6 582/4885KCNH2 2524/4885SCN5A 1186/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.